Literature DB >> 24101384

Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome.

Marc A Colaco1, Robert J Evans.   

Abstract

Bladder instillation therapy refers to the direct introduction of medication into the bladder and is a common treatment modality for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) who have failed conservative and oral therapies. The current American Urological Association (AUA) recommendations list three medications as options for IC/BPS instillation therapy: dimethyl sulfoxide, heparin, and lidocaine. The purpose of this review is to examine the evidence behind the recommendations for these medications. We also examine several historical or experimental therapies that do not hold recommendations but are still used on rare occasion. Finally, we discuss our bladder instillation strategies as well as potential future research and development in intravesicular therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24101384     DOI: 10.1007/s11934-013-0369-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  38 in total

Review 1.  Rational approaches to the treatment of patients with interstitial cystitis.

Authors:  Robert M Moldwin; Robert J Evans; Edward J Stanford; Matt T Rosenberg
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

2.  The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial.

Authors:  K Peters; A Diokno; B Steinert; M Yuhico; B Mitchell; S Krohta; B Gillette; J Gonzalez
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

3.  Non-anticoagulant uses of heparin.

Authors:  D A Lane; L Adams
Journal:  N Engl J Med       Date:  1993-07-08       Impact factor: 91.245

4.  Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome.

Authors:  Josefine Rössberger; Magnus Fall; Ralph Peeker
Journal:  Scand J Urol Nephrol       Date:  2005

5.  Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy.

Authors:  G M Ghoniem; D McBride; O P Sood; V Lewis
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

6.  Intravesical nanocrystalline silver decreases experimental bladder inflammation.

Authors:  W Boucher; J M Stern; V Kotsinyan; D Kempuraj; D Papaliodis; M S Cohen; T C Theoharides
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

7.  Chronic pelvic pain syndromes: clinical, urodynamic, and urothelial observations.

Authors:  Charles W Butrick; Dan Sanford; Qingijiang Hou; Jonathan D Mahnken
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05-21

8.  Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis.

Authors:  Gennady Slobodov; Michael Feloney; Christopher Gran; Kimberly D Kyker; Robert E Hurst; Daniel J Culkin
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

9.  Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat.

Authors:  Matthew O Fraser; Yao-Chi Chuang; Pradeep Tyagi; Teruhiko Yokoyama; Naoki Yoshimura; Leaf Huang; William C De Groat; Michael B Chancellor
Journal:  Urology       Date:  2003-03       Impact factor: 2.649

10.  A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis.

Authors:  J Curtis Nickel; Blair Egerdie; Joe Downey; Rajiva Singh; Anthony Skehan; Leslie Carr; Karen Irvine-Bird
Journal:  BJU Int       Date:  2008-09-03       Impact factor: 5.588

View more
  8 in total

1.  Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study.

Authors:  Shilpa Iyer; Elizabeth Lotsof; Ying Zhou; Alexis Tran; Carolyn Botros; Peter Sand; Roger Goldberg; Janet Tomezsko; Adam Gafni-Kane; Sylvia Botros
Journal:  Int Urogynecol J       Date:  2017-02-01       Impact factor: 2.894

2.  First evidence of neosaxitoxin as a long-acting pain blocker in bladder pain syndrome.

Authors:  Valentin Manríquez; Daniela Castro Caperan; Rodrigo Guzmán; Michel Naser; Veronica Iglesia; Nestor Lagos
Journal:  Int Urogynecol J       Date:  2015-01-09       Impact factor: 2.894

Review 3.  Interstitial cystitis intravesical therapy.

Authors:  Tanya Ha; Jie Hua Xu
Journal:  Transl Androl Urol       Date:  2017-07

4.  The Effect of Different Irrigation Solutions on the Cytotoxicity and Recovery Potential of Human Osteoblast Cells In Vitro.

Authors:  Jacob F Markel; Therese Bou-Akl; Paula Dietz; Alan M Afsari
Journal:  Arthroplast Today       Date:  2021-01-19

5.  Imatinib Mesylate-Loaded Rosin/Cinnamon Oil-Based In Situ Forming Gel against Colorectal Cancer Cells.

Authors:  Ei Mon Khaing; Torsak Intaraphairot; Jongjan Mahadlek; Siriporn Okonogi; Wiwat Pichayakorn; Thawatchai Phaechamud
Journal:  Gels       Date:  2022-08-23

Review 6.  Novel targeted bladder drug-delivery systems: a review.

Authors:  Martino Maria Zacchè; Sushma Srikrishna; Linda Cardozo
Journal:  Res Rep Urol       Date:  2015-11-23

Review 7.  Current guidelines in the management of interstitial cystitis.

Authors:  Marc Colaco; Robert Evans
Journal:  Transl Androl Urol       Date:  2015-12

8.  Is It Possible to Prevent Symptom Recurrence After Transurethral Resection for Hunner Lesion?

Authors:  Aram Kim; Jung Hyun Shin; Myung-Soo Choo
Journal:  Int Neurourol J       Date:  2018-06-30       Impact factor: 2.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.